MedTrace Logo

Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)

NCT01168024 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-12-12

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.

Conditions

  • Radiographic Contrast Agent Nephropathy

Interventions

DEVICE

CINCOR™ System and contrast conservation unit (CCS-1)

Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media

OTHER

Standard of Care plus peri-procedural hydration

The control group will receive a peri and post-procedural hydration rate.

Sponsors & Collaborators

  • Osprey Medical, Inc

    lead INDUSTRY

Principal Investigators

  • Gregg Stone, MD · CRF

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168024 on ClinicalTrials.gov